The Annual Report and Corporate Social Responsibility Report 2013 of JSC “Grindeks”

        Print
| Source: Grindeks
multilang-release

Riga, Latvia, 2014-07-08 10:24 CEST (GLOBE NEWSWIRE) --  

Today, on 8 July, the Annual Report and the Corporate Social Responsibility Report 2013 of JSC “Grindeks” were submitted to “NASDAQ OMX Riga”.

JSC “Grindeks” Chairman of the Board Juris Bundulis: “Following the patients' needs and market trends, "Grindeks" has achieved significant results in 2013. The company concluded the year of 2013 with turnover of 118.46 million euros and profit of 13.5 million euros. More information about the company’s activities is accessible in the Annual Report and the Corporate Social Responsibility Report 2013”.

About “Grindeks”

“Grindeks” is the leading pharmaceutical company in the Baltic States. Its main fields of action are: research, development, manufacturing and sale of original products, generics and active pharmaceutical ingredients. The Group of “Grindeks” consists of four subsidiary companies in Latvia, Estonia and Russia, as well as representative offices in 13 countries.

“Grindeks” specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups. A range of products covers a successful combination of original products and generics, with the original products Mildronate® and Ftorafur® and more than 100 forms of effective and safe generics included therein. Currently “Grindeks” produces 25 active pharmaceutical ingredients.

Products of the company are exported to 59 countries and its export comprises more than 95% of the total turnover. The main markets are: Russia and other CIS countries, the Baltic States, Germany, the Netherlands, Japan and the U.S.

To increase production capacity and develop infrastructure, since 2002 the company has accomplished many significant investment projects, investing 70.7 million euros over the years.

JSC “Grindeks” shares are listed on the Official List of “NASDAQ OMX Riga”. Major shareholders of JSC “Grindeks” are Kirovs Lipmans – 33.29%, “AB.LV Private Equity fund 2010” – 22.66%, Anna Lipmane – 16.69%, “Swedbank” AS Clients Account (nominee account) – 10.47%.

More information about the company – www.grindeks.lv/en/

Follow “Grindeks”:
Twitter.com/AS_Grindeks; Youtube.com/GrindeksLV 

 

         Further information:
         Laila Kļaviņa
         Head of the Communications Department, JSC “Grindeks”
         Phones: (+371) 67083370, (+371) 29256012
         Fax: (+371) 67083505
         laila.klavina@grindeks.lv